Personalis, Inc. to Present at NeoAg Summit US 2019
The presentation, entitled “ImmunoID NeXT: A Comprehensive Platform for Improving Neoantigen Prediction, Tumor Escape Mechanism Reporting, TME Assessment, and Tumor Heterogeneity Profiling for Immuno-Oncology,” will provide an overview of Personalis’ newly-launched cancer immunogenomics platform, specifically highlighting innovative machine learning-based methods for the comprehensive identification of neoantigens and the detection of emerging and novel biomarkers of response and resistance to immunotherapy.
ImmunoID NeXT™ is the first platform to enable comprehensive analysis of both a tumor and its immune microenvironment from a single sample. ImmunoID NeXT™ can be used to investigate the key tumor- and immune-related areas of cancer biology, consolidating multiple oncology biomarker assays into one and maximizing the biological information that can be generated from a precious tumor specimen.
The presentation will be delivered by
About
View source version on businesswire.com: https://www.businesswire.com/news/home/20191121005329/en/
Source:
Media Contact for Personalis:
Jennifer Havlek
pr@personalis.com
www.personalis.com
650-752-1300
Investor Relations Contact for Personalis:
Caroline Corner
investors@personalis.com
www.westwicke.com
415-202-5678